Market Overview

FDA Issues Review of Hemispherx's Ampligen Lacks Required Carcinogencity Tests

Share:
Related HEB
Hemispherx Biopharma Agress To Sell Up To $75M Of Common Stock
Technicians: Watch Finisar, VirnetX, GoPro, Glu Mobile & BlackBerry

View document.

Posted-In: News FDA

 

Related Articles (HEB)

Around the Web, We're Loving...

Get Benzinga's Newsletters